Steglatro

Quote
the other SGLT2s already give their drugs away with copay cards. It would be impossible for us to sell our drug at a discount to others. we can match their discount but not better it
this is going to be a tremendous waste of thousands of peoples time
but at least we get paid to waste our time
 






anonymous said:
the other SGLT2s already give their drugs away with copay cards. It would be impossible for us to sell our drug at a discount to others. we can match their discount but not better it
this is going to be a tremendous waste of thousands of peoples time
but at least we get paid to waste our time
Click to expand...
This drug looks to be outstanding. Get ready to make a lot of money selling it. Relationships Merck reps have in diabetes market will significantly help sell a lot of Steglatro
 












anonymous said:
This drug looks to be outstanding. Get ready to make a lot of money selling it. Relationships Merck reps have in diabetes market will significantly help sell a lot of Steglatro
Click to expand...
This drug will do very well with the relationships Merck reps have plus combo with Januvia. Merck will maintain their leadership in diabetes. Managers are getting great reception from endos as they launch Steglatro and they like the combo with the leader Januvia. Great set of drugs.
 






anonymous said:
Managers are meeting and getting all you need to be successful with Steglatro. Great meeting. This drug will be a leader with managers selling it to endos and the outstanding strategy. Merck will remain the leader in diabetes.
Click to expand...
How are the managers doing with the endos? What managed care coverage is there?
 
























anonymous said:
This drug will do very well with the relationships Merck reps have plus combo with Januvia. Merck will maintain their leadership in diabetes. Managers are getting great reception from endos as they launch Steglatro and they like the combo with the leader Januvia. Great set of drugs.
Click to expand...

LOL this is comedy gold
 






anonymous said:
This drug looks to be outstanding. Get ready to make a lot of money selling it. Relationships Merck reps have in diabetes market will significantly help sell a lot of Steglatro
Click to expand...
That is hilarious!!
Don’t forget fair balance and discuss amputation data. “Yes doctor, we have a warning for amputations and a HUGE imbalance versus placebo but at least it’s not a black box warning like canagliflozin and it’s also free like farxiga!!!!”
 












anonymous said:
Are the endos accepting that Steglatro offers a lot for patients. Are they writing it?
Click to expand...
NOPE! The combination has been available for years with the Lilly product so nothing new! What about the CV indication? We have been in the diabetes space for years and we can't even come to market with a CV indication! I guess evidence based medicine no longer means anything to Merck leadership.
 






anonymous said:
Remember. The Merck salesforce is very adept at selling. They will give it away and get on formularies and this drug will lead the market within 2 years. Remember an older group at Merck with multiple relationships, relationships, relationships. Buy Merck!!!
Buy Merck!!!!
Click to expand...
You may be the single biggest moron left at Merck. And that's saying something.
 


















Sorry guys. You will have a tough go of it. Ask your leadership, “How much glucose is offloaded daily with steg?” Unfortunately for you, lowest in class. Ask them,”What percent of T2DM pts have an eGFR of <60?” Ask them, “If Invo was impacted by its 2 fold increase in amputations, how will customers react to a 5 fold increase with Steg?” CV benefit not as big a deal as you might think. After all, I know you guys have been selling against SULF’s for years. What kind of market share does that class have? And you know what is in the warnings and precautions with SULF’s with regard to CV mortality. Ultimately, it will come down to dollars and cents.
 






As you said nobody cares about CV data. They should. With the experienced salesforce with all these great relationships intact Steglatro should do well. My boss has had very positive reactions to message and says with the better than average managed care positioning as well as the fact that Januvia is so well written, Steglatro should be a walk in the park
 












anonymous said:
As you said nobody cares about CV data. They should. With the experienced salesforce with all these great relationships intact Steglatro should do well. My boss has had very positive reactions to message and says with the better than average managed care positioning as well as the fact that Januvia is so well written, Steglatro should be a walk in the park
Click to expand...
Relationships don't mean S#!t Withou a CV indication. Also fourth to market means the only traction we can get is by giving the steglatro component away in the combo. Leadership learned nothing from Dulera.
 






To prior poster, my understanding is that this is asymmetric access. If you have some sort of access, it is sold, but if not, staying with Januvia at the moment. I am touching it and gently selling STEG and MD's are not that receptive right now...
 






Top Bottom
Back
Quote